The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection

E. C. Cheon, W. Small, M. J. Strouch, S. B. Krantz, A. Rademaker, M. F. Mulcahy, A. B. Benson, D. J. Bentrem, M. S. Talamonti

Research output: Contribution to journalReview article

6 Scopus citations


Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.

Original languageEnglish (US)
Pages (from-to)539-542
Number of pages4
JournalJournal of surgical oncology
Issue number5
StatePublished - Oct 1 2010



  • Avastin
  • Bevacizumab
  • Chemoradiation
  • Postoperative complication

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this